Drug development in Innsbruck | DiePresse.com
The Med-Uni Innsbruck and the University of Innsbruck are starting a joint course of study on the development and approval of medicinal products.
The importance and complexity of drug development and approval has been in general awareness since Corona. But even apart from Covid-19, the development of new drugs is booming. The Karl-Franzens-University Innsbruck and the Med-Uni Innsbruck are starting a joint master’s degree in “Pharmaceutical Sciences – Drug Development and Regulatory Affairs” in autumn, which is intended to provide the necessary skills.
The spectrum of topics ranges from preclinical and clinical studies to approval and market launch. In addition to the lecturers from both universities, the lecturers include experts from the pharmaceutical industry and the regulatory authorities. Graduates should be able to plan and carry out complex drug development projects independently, and are thus equipped to work in pharmaceutical companies, clinical testing organizations, drug authorities and many other institutions and companies in the healthcare sector. An intensive practical module in one of these institutions is a relevant element of the course.
The master’s program also deals with a graduate of a bachelor’s degree in pharmacy, chemistry, biology or molecular medicine. The four-semester Master’s program is organized as a full-time course and is held in English. Graduates receive a title from the University of Innsbruck and a joint certificate from both universities involved. In addition to a test that examines knowledge of the relevant natural sciences and statistics, the admissions procedure includes a personal interview. The application deadline is May 13th.
Network: www.ubik.ac.at , www.i-med.ac.at